Zuiderbuur schreef op 22 juni 2017 20:13:
[...]
Gevonden in de conference call van 17 december 2015 (Gilead-deal):
"Onno van de Stolpe - Galapagos NV - CEO
We have kept the discussion solely on filgotinib to keep the discussion simple, as we wanted to get the deal done in a very short period of time.
And so, we said, this is the asset that we want to partner, and that's it.
We have negotiated exclusivity on the JAKs for all diseases except for oncology. We keep all the JAKs that we have in-house -- the JAK molecules that we can develop for oncology. Gilead is also free to develop anything they want in oncology, independent of Galapagos.
We have excluded from the transaction one JAK molecule that we have as a candidate. It's actually a selective JAK1 PIK2 molecule that we will develop independently from Gilead, and Gilead has the first right to negotiate; not the first right of refusal, but the first right to negotiate after we conclude Phase I studies. So, that's the only thing that we discussed apart from filgotinib."
Gilead is dus vrij om filgotinib te ontwikkelen in oncologie als ik het goed begrijp. Maar wat er zou gebeuren in geval van succes is mij nog niet duidelijk.